Every year over 2 million people die from bleeding after major rauma. As a potentially preventable cause of death, trauma haemrrhage is an important area for research and innovation. There ave been dramatic changes in practice recently, including the ntroduction of ‘haemostatic resuscitation’ protocols.1 Previously, esuscitation of haemorrhagic shock was focused on restoring irculating volume and organ perfusion. Coagulopathy was conidered a consequence of dilution or loss of clotting factors and herefore a late event in the clinical course. Replacement of coaglation factors was considered to be required relatively late in the linical course and only after the administration of large volumes of ed cell transfusions. This approach was challenged with the discovry of acute traumatic coagulopathy (ATC), which develops within inutes of injury, exacerbates haemorrhage and is associated with igh mortality rates.2 The new haemostatic resuscitation protocols arget ATC, giving large doses of plasma and platelet therapies much arlier and concurrent with red cell transfusions. Early studies sugest this approach may significantly improve outcomes in trauma aemorrhage. For these protocols to be effective, bleeding patients must be dentified early in their clinical course, as there are logistic issues n the rapid provision of plasma and platelet transfusions. There is n intrinsic conflict between the need for more blood products to e delivered as quickly as possible, and the importance of avoiding nnecessary transfusions or the waste of a precious resource. Idelly therefore we should be able to identify rapidly people who ill require large blood product transfusions. In practice this is ot a straightforward process. In a multicentre study of over five housand patients, variables that were most predictive of massive ransfusion were admission systolic blood pressure, base deficit, njury severity score and prothrombin time.3 However, only the rst two of these are readily available on admission, and a predicive tool using these parameters achieved only a 50–70% specificity t a 90% sensitivity threshold. Other massive transfusion prediction ools have had similar performance, and while attractive in their implicity, will still result in late activation or over transfusion in any cases.4–6 As admission coagulopathy is highly predictive of subsequent ransfusion requirements, the early diagnosis of ATC would signifcantly improve the activation accuracy of massive haemorrhage rotocols. Additionally, the administration of fresh frozen plasma o patients without coagulopathy has been shown to have no addiional benefits on clotting function.7 Traditional laboratory tests f coagulation, such as the prothrombin time, are not suitable for uiding transfusion therapy. Results are not available in a use-
[1]
Lesly A. Dossett,et al.
Multicenter validation of a simplified score to predict massive transfusion in trauma.
,
2010,
The Journal of trauma.
[2]
R. Pearse,et al.
Hemostatic effects of fresh frozen plasma may be maximal at red cell ratios of 1:2.
,
2011,
The Journal of trauma.
[3]
C. Thiemermann,et al.
Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations
,
2010,
Journal of thrombosis and haemostasis : JTH.
[4]
R. Lefering,et al.
Revalidation and update of the TASH‐Score: a scoring system to predict the probability for massive transfusion as a surrogate for life‐threatening haemorrhage after severe injury
,
2011,
Vox sanguinis.
[5]
Jose Salinas,et al.
A predictive model for massive transfusion in combat casualty patients.
,
2008,
The Journal of trauma.
[6]
Biswadev Mitra,et al.
Early prediction of acute traumatic coagulopathy.
,
2011,
Resuscitation.
[7]
J. Dellavolpe,et al.
Hemostatic resuscitation during surgery improves survival in patients with traumatic-induced coagulopathy.
,
2009,
The Journal of trauma.
[8]
M. Cohen,et al.
Reappraising the concept of massive transfusion in trauma
,
2010,
Critical care.